Spectrum Pharmaceuticals, Inc.
SPPI

$210.38 M
Marketcap
$1.03
Share price
Country
$-0.01
Change (1 day)
$1.57
Year High
$0.32
Year Low
Categories

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

marketcap

Revenue of Spectrum Pharmaceuticals, Inc. (SPPI)

Revenue in 2022 (TTM): $10.11 M

According to Spectrum Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $10.11 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Spectrum Pharmaceuticals, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2022 $10.11 M $8.32 M $-77,060,000 $-78,058,000 $-78,104,000
2021 $ $ $-147,703,000 $-158,432,000 $-158,436,000
2020 $ $ $-169,734,000 $-171,332,000 $-171,272,000
2019 $22.62 M $10.61 M $-140,698,000 $-144,594,000 $-135,386,000
2018 $109.33 M $82.58 M $-93,499,000 $-120,010,000 $-120,011,000
2017 $128.37 M $81.15 M $-68,624,000 $-108,026,000 $-91,248,000
2016 $146.44 M $110.6 M $-34,795,000 $-70,825,000 $-68,512,000
2015 $162.56 M $134.87 M $-3,662,000 $-50,379,000 $-50,785,000
2014 $186.83 M $159.79 M $-11,648,000 $-43,533,000 $-45,719,000
2013 $155.85 M $127.27 M $-21,582,000 $-36,636,000 $-62,134,000
2012 $267.71 M $221.07 M $86.57 M $78.98 M $94.55 M
2011 $192.96 M $159.13 M $63.69 M $52.22 M $48.52 M
2010 $74.11 M $56.67 M $-52,401,000 $-48,887,000 $-48,844,000
2009 $38.03 M $29.88 M $-25,450,000 $-19,771,000 $-19,046,000
2008 $28.73 M $27.53 M $-10,325,000 $-22,705,000 $-15,467,000
2007 $7.67 M $7.67 M $-40,079,000 $-34,056,000 $-34,036,000
2006 $5.67 M $5.58 M $-26,276,000 $-25,312,000 $-23,284,000
2005 $577 K $180 K $-20,519,000 $-18,643,000 $-18,642,000
2004 $258 K $135 K $-12,377,000 $-12,798,000 $-12,286,000
2003 $1000 K $1000 K $-9,808,000 $-10,619,000 $-10,390,000
2002 $2.37 M $2.37 M $-9,915,514 $-20,721,231 $-17,633,861
2001 $41.11 K $41.11 K $-25,678,709 $-28,350,566 $-27,834,820
2000 $1 $1.13 M $-42,736,860 $-43,882,397 $-46,427,287
1999 $1 $519.88 K $-20,779,889 $-25,746,494 $-25,989,905
1998 $100 K $600 K $-11,200,000 $-11,300,000 $-11,600,000
1997 $100 K $300 K $-7,200,000 $-6,000,000 $-6,200,000
1996 $100 K $100 K $-1,500,000 $-900,000 $-1,000,000